Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANEXSIA 5/325 vs ESIMIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.
Fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide. Olmesartan is an angiotensin II receptor blocker (ARB) that inhibits vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle, causing vasodilation. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal tubule.
Management of moderate to moderately severe pain where an opioid analgesic is appropriate
Hypertension (to lower blood pressure, not for initial therapy)
1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
5 mg orally once daily, may increase to 10 mg once daily after 2-4 weeks if needed.
Oxycodone: terminal half-life 3.2-4.3 hours (immediate-release); prolonged in hepatic impairment. Acetaminophen: terminal half-life 2-3 hours (therapeutic doses); prolonged in hepatic impairment or overdose.
2.3 ± 0.4 hours; prolonged in renal impairment (up to 6.5 hours in severe cases).
Hydrocodone: primarily hepatic via CYP3A4 and CYP2D6 to active metabolites (hydromorphone). Acetaminophen: hepatic metabolism via conjugation (glucuronidation, sulfation) and CYP2E1-mediated oxidation to toxic NAPQI.
Olmesartan: undergoes hepatic ester hydrolysis to active metabolite, not metabolized by CYP450 system. Amlodipine: extensively metabolized in liver via CYP3A4. Hydrochlorothiazide: not significantly metabolized.
Oxycodone: renal excretion of metabolites (conjugated and unconjugated) and parent drug; ~10% excreted unchanged. Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates); ~2-4% excreted unchanged.
Primarily renal (>90% as unchanged drug); biliary/fecal <10%.
Oxycodone: 38-45% bound to albumin and alpha-1-acid glycoprotein. Acetaminophen: 10-25% bound to albumin at therapeutic concentrations.
40-50% bound to albumin.
Oxycodone: Vd 2.0-3.0 L/kg; distributes extensively into tissues. Acetaminophen: Vd 0.8-1.0 L/kg; relatively uniform distribution.
1.5-2.0 L/kg; suggests extensive tissue distribution.
Oxycodone: oral bioavailability 60-87% (immediate-release). Acetaminophen: oral bioavailability 88-98% (therapeutic doses).
Oral: 55-65% due to first-pass metabolism.
GFR 30-50 m L/min: use with caution, increase dosing interval to every 6 hours; GFR <30 m L/min: avoid use due to hydrocodeone accumulation.
e GFR 30-89 m L/min: no adjustment. e GFR <30 m L/min: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: not recommended.
Not recommended for children under 18 years due to risk of respiratory depression.
Not approved for pediatric use; safety and efficacy not established.
Start with lowest dose (1 tablet every 6 hours), monitor renal and hepatic function, and avoid in frail elderly due to increased fall and cognitive impairment risk.
Start at 2.5 mg once daily due to increased sensitivity and risk of adverse effects.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and hepatotoxicity from acetaminophen overdose.
Discontinue as soon as possible when pregnancy is detected. Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity; adrenal insufficiency; severe hypotension; gastrointestinal obstruction; seizure; and serotonin syndrome.
Fetal toxicity (see black box warning),Hypotension in volume-depleted patients,Monitor renal function; may increase serum creatinine and BUN,Electrolyte disturbances (hypokalemia, hyponatremia, hypercalcemia),Exacerbation of angina or acute MI (especially with rapid dose increase of amlodipine),Acute angle-closure glaucoma (with HCTZ),Systemic lupus erythematosus exacerbation (with HCTZ),Metabolic acidosis (with HCTZ),Avoid use in patients with severe renal impairment (Cr Cl <30 m L/min)
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; severe hepatic impairment; and concurrent use of MAOIs within 14 days.
Hypersensitivity to any component,Anuria (due to HCTZ),Concomitant use with aliskiren in patients with diabetes
Avoid alcohol. Grapefruit juice may enhance side effects; limit intake. Take with food to reduce gastrointestinal discomfort.
Food may delay absorption; take on an empty stomach for best results. Avoid acidic beverages (e.g., orange juice) within 30 minutes of dosing. No significant food restrictions but a low-acid diet may help symptom control.
First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal renal toxicity, oligohydramnios, and premature closure of ductus arteriosus. Use only if clearly needed.
Esimil (pseudoephedrine) is classified as FDA Pregnancy Category C. In the first trimester, there is limited data but a potential risk of gastroschisis has been suggested in some retrospective studies. In the second and third trimesters, use may be associated with reduced uterine blood flow and fetal tachycardia; avoid near term due to risk of neonatal irritability. Overall, use only if clearly needed and after first trimester.
Paracetamol and hydrocodone are excreted in breast milk. M/P ratio: paracetamol ~1.0, hydrocodone ~1.0-2.0. Use with caution; monitor infant for drowsiness and respiratory depression. Consider risk of infant sedation with long-term use.
Pseudoephedrine is excreted into breast milk in small amounts (M/P ratio ~2.5-3.5). It may reduce milk production, especially with chronic use. The relative infant dose is estimated at 2-5% of maternal weight-adjusted dose. Caution is advised; monitor infant for irritability, sleep disturbances, and feeding problems.
Increased clearance in pregnancy may require dose adjustment. Monitor for pain control and adverse effects; no fixed dose change recommended. Consider lower starting dose due to potential fetal risks. Avoid chronic use; taper if possible.
No standard dose adjustments are recommended, but due to increased renal clearance in pregnancy, therapeutic effects may be reduced. Use the lowest effective dose for the shortest duration. Avoid sustained-release formulations in pregnancy due to unpredictable absorption.
ANEXSIA 5/325 contains hydrocodone 5 mg and acetaminophen 325 mg. Maximum acetaminophen dose from all sources should not exceed 4 g/day in adults; avoid in severe hepatic impairment. Hydrocodone is a Schedule II controlled substance with abuse potential; monitor for respiratory depression, especially in opioid-naive patients. Use with caution in patients with COPD, sleep apnea, or increased intracranial pressure. Consider naloxone co-prescription for high-risk patients. For acute pain, limit duration to 3-7 days.
ESIMIL (esomeprazole) is a proton pump inhibitor (PPI) used for acid-related disorders. Onset of action is rapid, but maximal acid suppression occurs after 5-7 days. Best taken before breakfast for optimal effect. Avoid co-administration with clopidogrel due to reduced efficacy. Monitor magnesium levels with prolonged use, especially in patients taking diuretics or digoxin. Consider calcium and vitamin D supplementation to mitigate osteoporosis risk.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not consume alcohol or other sedatives (e.g., benzodiazepines) while taking this medication.,Avoid other products containing acetaminophen (e.g., Tylenol, cold remedies) to prevent liver damage.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Store securely out of reach of others; dispose of unused medication via drug take-back programs.,Seek emergency help if you have trouble breathing, severe drowsiness, or signs of allergic reaction.
Take this medication 30-60 minutes before a meal, preferably breakfast.,Swallow capsules whole; do not crush or chew.,Do not take with other acid reducers unless directed.,Report symptoms of severe diarrhea, bone pain, or muscle cramps.,Avoid alcohol and spicy foods that may worsen symptoms.,Long-term use may increase risk of fractures; ensure adequate calcium intake.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANEXSIA 5/325 vs ESIMIL, answered by our medical review team.
ANEXSIA 5/325 is a Opioid Analgesic Combination that works by Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.. ESIMIL is a Unknown that works by Fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide. Olmesartan is an angiotensin II receptor blocker (ARB) that inhibits vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle, causing vasodilation. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal tubule.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANEXSIA 5/325 and ESIMIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANEXSIA 5/325 is: 1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. The standard adult dose of ESIMIL is: 5 mg orally once daily, may increase to 10 mg once daily after 2-4 weeks if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANEXSIA 5/325 and ESIMIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANEXSIA 5/325 is classified as Category C. First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal re. ESIMIL is classified as Category C. Esimil (pseudoephedrine) is classified as FDA Pregnancy Category C. In the first trimester, there is limited data but a potential risk of gastroschisis has been suggested in some r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.